Wire · operational-macro
FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 October 2026 · Fusion42 review
The FDA has approved Edwards Lifesciences' PASCAL Precision system for transcatheter tricuspid valve repair, expanding treatment options for patients with severe tricuspid regurgitation who are at intermediate or higher surgical risk. Additionally, the PASCAL Ace with Capture Clarity system received FDA approval for mitral valve repair, enhancing procedural efficiency with new fluoroscopic indicators.
This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 21 Oct 2026 and 22 Oct 2026.
◆ ◆ The Wire takeaway
You now compete in a wider US heart valve repair market where Edwards leads with the only combined mitral and tricuspid device portfolio. New device features cut procedure complexity, letting you pitch faster clinical wins to hospitals.
◆ Coverage
3 sources · first reported 21 Oct 2026 · latest 22 Oct 2026
◆ Related on Wire
◆ Topics